Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

CT Screening Evolves Amid Questions and Controversy

October 10th 2012

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

No Survival Benefit With Add-On Sorafenib in Advanced Lung Cancer

October 9th 2012

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

From Survivor to Advocate: How One Patient Launched Two Foundations

October 5th 2012

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

Molecular Discoveries Pave Way for Rapid Advances in Lung Cancer

October 5th 2012

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

Tivantinib Study Halted Following Interim Analysis

October 3rd 2012

The phase III MARQUEE trial examining tivantinib has been halted following a planned interim analysis because it was not expected to meet its primary endpoint.

Positive Results in ALK-Positive NSCLC With First ALK Inhibitor

October 1st 2012

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

Bonnie Addario Discusses the Stigma of Lung Cancer

September 19th 2012

Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.

Dr. Spigel Discusses the Evolving NSCLC Treatment Landscape

September 14th 2012

Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.

Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

September 14th 2012

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Targeted Therapy Combination Slows NSCLC

September 14th 2012

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

Mutation Confers Anti-EGFR Resistance

September 14th 2012

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Hint of Survival Benefit in NSCLC With Bavituximab Plus Docetaxel

September 13th 2012

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

Dr. Gandara on Patient Selection for Molecular Testing

September 12th 2012

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Alimta Combination Fails Survival Objectives in Phase III Study

September 6th 2012

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Rash Signals Better Outcome for Erlotinib Therapy in NSCLC

September 5th 2012

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

Dr. Scagliotti on Targeted Therapies and Chemotherapy

August 31st 2012

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. Langer Discusses Treating Locally Advanced NSCLC

August 29th 2012

Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.

5 ALK-Related Questions for D. Ross Camidge, MD, PhD and Fredika M. Robertson, PhD

August 27th 2012

Two leading researchers discuss the role of the ALK signaling pathway and development into new ALK-targeted anticancer therapies.

ALK Inhibitors: Moving Rapidly From Discovery to Clinical Approval and Beyond

August 27th 2012

There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.

NEXT PAGE
PREVIOUS PAGE